Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.45 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508710 | 0.84 | LMNA (0.42) | TLR8KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6639388 | 0.71 | TLR8 (0.47) | TLR8ARG1KCNH2CYP1A2CYP2C9 | |
| SCHEMBL6641714 | 0.71 | TLR8 (0.44) | TLR8ARG1KCNH2TSHRTYMP | |
| SCHEMBL7120556 | 0.71 | CHRNB2 (0.47) | CYP1A2CYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL6639142 | 0.71 | LMNA (0.52) | TLR8LMNAGAAL3MBTL1KMT2A | |
| SCHEMBL6637907 | 0.70 | TLR8 (0.43) | TLR8ARG1KCNH2TSHRLMNA | |
| SCHEMBL6636184 | 0.69 | TLR8 (0.49) | TLR8ARG1KCNH2TSHRTYMP | |
| SCHEMBL27658200 | 0.69 | TLR8 (0.67) | TLR8ARG1KCNH2TSHRALDH1A1 | |
| SCHEMBL3648737 | 0.68 | — | — | |
| SCHEMBL6642531 | 0.68 | TLR8 (0.47) | TLR8ARG1KCNH2TSHRTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1185521-B1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | claimed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | claimed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | claimed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | claimed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| EP-1185521-B1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| CN-1366521-A | Substituted 1-aza-2-imino heterocycles and their use as nicotinic acetylcholine receptors activators | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-1185521-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS ACTIVATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | SUNTORY LIMITED (JP) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001081326-A1 | SUBSTITUTED 1-AZA-2-IMINO-HETEROCYCLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTORS ACTIVATORS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134848-A1 | Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators | CHRNA7, CHRNA2, CHRNA1 | TLR8 1132/4885ARG1 1993/4885KCNH2 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.